Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 4/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426935 | 0.83 | ITGB3 (0.43) | — | |
| SCHEMBL1628159 | 0.80 | MAOB (0.43) | ROCK1 | |
| SCHEMBL1625904 | 0.79 | KDM4E (0.41) | HRH4NMT1ACHEQPCTKDM1A | |
| SCHEMBL426645 | 0.79 | HRH4 (0.44) | HRH4NMT1KDM2BACHEROCK1 | |
| SCHEMBL1626586 | 0.79 | HRH4 (0.43) | HRH4NMT1CTSLCTSSCTSK | |
| SCHEMBL3422128 | 0.78 | HRH4 (0.51) | HRH4NMT1ACHEQPCTCTSL | |
| SCHEMBL3422672 | 0.78 | ALDH1A1 (0.46) | — | |
| SCHEMBL2193036 | 0.77 | HPGD (0.43) | — | |
| SCHEMBL3425503 | 0.77 | HRH4 (0.44) | HRH4NMT1QPCT | |
| SCHEMBL3422676 | 0.77 | HRH4 (0.44) | HRH4NMT1ACHEQPCTCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737297-B1 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-19 | — | — | EP | disclosed |
| US-8039498-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-10-18 | — | — | US | disclosed |
| US-8017639-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-8017600-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-7956057-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7956066-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7956071-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7951808-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7928131-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20100261899-A1 | IMIDAZOLE COMPOUNDS | BUZARD DANIEL J | 2010-10-14 | — | — | US | disclosed |
| US-20100261898-A1 | IMIDAZOLE COMPOUNDS | BUZARD DANIEL J | 2010-10-14 | — | — | US | disclosed |
| US-20070265250-A1 | Imidazole compounds | BUZARD DANIEL J | 2007-11-15 | — | — | US | disclosed |
| US-7253200-B2 | Using in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| US-20070173512-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173509-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173510-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173513-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173512-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885NMT1 1679/4885KDM2B 1334/4885 |
| US-20100261898-A1 | IMIDAZOLE COMPOUNDS | HRH4, HRH3, HRH2 | HRH4 1/4885NMT1 1679/4885KDM2B 1334/4885 |
| US-20070173509-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885NMT1 1679/4885KDM2B 1334/4885 |
| US-20070149541-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885NMT1 1679/4885KDM2B 1334/4885 |
| US-20070173510-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885NMT1 1679/4885KDM2B 1334/4885 |
| US-20070265250-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885NMT1 1679/4885KDM2B 1334/4885 |
| US-20100261899-A1 | IMIDAZOLE COMPOUNDS | HRH4, HRH3, HRH2 | HRH4 1/4885NMT1 1679/4885KDM2B 1334/4885 |
| US-20070173513-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885NMT1 1679/4885KDM2B 1334/4885 |
| US-20050261309-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HRH4 1/4885NMT1 1679/4885KDM2B 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.